

## 2 Months

Study	Country	Design						VE (95% CI)
Patalon et al. (46)	Israel	TN					H	0.97 (0.95, 0.98)
Lin et al. (24) (Sep-Nov '21)	USA	С				H <del>≡</del> I		0.81 (0.78, 0.83)
Hulme et al. (75)	UK	MC				<del>  =  </del>		0.85 (0.82, 0.87)
Florea et al. (79)	USA	MC				H	H	0.89 (0.85, 0.92)
Ranzani et al. (38)	Brazil	MTN				<del>  -  </del>		0.72 (0.70, 0.74)
Stirrup et al. (86)	UK	С				•	-	0.81 (0.48, 0.93)
Ng et al. (76)	Singapore	С				<del></del>		0.85 (0.80, 0.89)
Gonzalez et al. (80)	Argentina	MTN				<del>  ■  </del>		0.72 (0.68, 0.75)
Lin et al. (24) (Dec '21-Jun '22)	USA	С				<del></del>		0.73 (0.69, 0.77)
Ridgway et al. (29)	USA	MCC				<b>├-</b>		0.76 (0.70, 0.82)
			0	0.25 Vaccine	0.5 Effectivene	0.75 ss (VE)	1	

## 3 Months

Study	Country	Design		VE (95% CI)
Lin et al. (24) (Sep-Nov '21)	USA	С	<b>├-</b>	0.74 (0.70, 0.78)
Florea et al. (79)	USA	MC		0.79 (0.54, 0.90)
Ranzani et al. (38)	Brazil	MTN	<del> ■ </del>	0.67 (0.65, 0.69)
Stirrup et al. (86)	UK	С	<del>                                     </del>	0.85 (0.68, 0.93)
Gonzalez et al. (80)	Argentina	MTN	<b>├──</b>	0.48 (0.39, 0.56)
Lin et al. (24) (Dec '21-Jun '22)	USA	С	<b>├─■</b> ─ <b>│</b>	0.63 (0.57, 0.68)
Ridgway et al. (29)	USA	MCC	0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	0.76 (0.71, 0.80)